Tag: BMS-986278
Bristol Myers’ BMS-986278 yields promising results in slowing pulmonary fibrosis progression in Phase 2 trial
Bristol Myers Squibb (NYSE: BMY) disclosed a pivotal Phase 2 study highlighting that BMS-986278, an investigational oral LPA1 antagonist, reduces the rate of lung function ... Read More
BMS-986278 succeeds in phase 2 idiopathic pulmonary fibrosis trial, says Bristol Myers Squibb
Bristol Myers Squibb (BMS) said that BMS-986278 has succeeded in lowering the rate of lung function decline in idiopathic pulmonary fibrosis patients in a phase ... Read More